Scientists are developing dog weight loss drugs that work like Ozempic in humans, and they could be on the market as soon as ...

Vivani Medical announced that it brought in $10 million in equity financing as it progresses its drug delivery technology.

Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing preclinical study of NPM-139 and promising results from the LIBERATE-1 Phase 1 clini ...

Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing ...

Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing preclinical study of NPM-139 and promising results from the LIBERATE-1 Phase 1 clini ...

LIBERATE-1, the first-in-human application of Vivani’s NanoPortalTM implant technology, showed a positive safety and tolerability profile, along with ...

LIBERATE-1, the first-in-human application of Vivani’s NanoPortalTMimplant technology, showed a positive safety and tolerability profile, along with encouraging performance data for NPM-115 that met t ...

Vivani reported Phase 1 success for its exenatide implant and shared preclinical semaglutide data showing 231-day weight loss ...

Oral semaglutide was associated with more pronounced cardiovascular benefits among patients with higher baseline HbA1c in type 2 diabetes.

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic versions of Novo Nordisk’s lucrative semaglutide drugs for diabetes and ...

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.